Stockholm - Delayed Quote SEK

Aptahem AB (publ) (APTA.ST)

Compare
1.6400 -0.0100 (-0.61%)
At close: October 18 at 4:20 PM GMT+2

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Dr. Bert Junno Co-Founder & Chairman of the Board -- -- 1966
Mr. Mikael Lindstam Co-Founder, CEO & Director -- -- 1966
Dr. Luiza Jedlina Co-Founder & CSO -- -- --
Mr. Ola Skanung Chief Financial Officer -- -- 1964

Aptahem AB (publ)

Norra Vallgatan 58, 4TR
Malm?, 211 22
Sweden
46 7 66 02 01 99 https://www.aptahem.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
5

Description

Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children's Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malm?, Sweden.

Corporate Governance

Aptahem AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers